At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORIC Oric Pharmaceuticals Inc.
Pre-Mkt 11-03 08:14:03 EST
9.07
-0.17
-1.84%
盘前9.15
+0.08+0.88%
08:06 EST
High9.38Low9.00Vol1.92M
Open9.29D1 Closing9.24Amplitude4.11%
Mkt Cap938.90MTradable Cap804.39MTotal Shares103.52M
T/O17.54MT/O Rate2.17%Tradable Shares88.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Oric Pharmaceuticals Price Target Maintained with a $26.00/Share by BTIG
Dow Jones  ·  10-28
Oric Pharmaceuticals Price Target Maintained with a $26.00/Share by BTIG
Oric Pharmaceuticals (ORIC) Receives a Buy from Wedbush
TIPRANKS  ·  10-27
Oric Pharmaceuticals (ORIC) Receives a Buy from Wedbush
Oric Pharmaceuticals selloff on J&J data ‘way overdone,’ says Cantor Fitzgerald
TIPRANKS  ·  10-27
Oric Pharmaceuticals selloff on J&J data ‘way overdone,’ says Cantor Fitzgerald
Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating
MT Newswires Live  ·  10-27
Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating
US Research Roundup- Clearwater Paper, Molina Healthcare, Qualys
Reuters  ·  10-27
US Research Roundup- Clearwater Paper, Molina Healthcare, Qualys
Oric Pharmaceuticals, Inc. : Wedbush Cuts Target Price to $14 from $17
THOMSON REUTERS  ·  10-27
Oric Pharmaceuticals, Inc. : Wedbush Cuts Target Price to $14 from $17
Oric Pharmaceuticals is Maintained at Buy by Stifel
Dow Jones  ·  10-27
Oric Pharmaceuticals is Maintained at Buy by Stifel
Oric Pharmaceuticals drops after J&J presents prostate cancer drug data
TIPRANKS  ·  10-26
Oric Pharmaceuticals drops after J&J presents prostate cancer drug data
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC)
TIPRANKS  ·  10-26
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC)
Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Oric Pharmaceuticals (ORIC)
TIPRANKS  ·  10-23
Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Oric Pharmaceuticals (ORIC)
Oric Pharmaceuticals presents enozertinib data at ESMO Congress
TIPRANKS  ·  10-23
Oric Pharmaceuticals presents enozertinib data at ESMO Congress
ORIC Pharmaceuticals Plans Phase 3 Enozertinib Trial in Lung Cancer for First Half of 2027
Reuters  ·  10-23
ORIC Pharmaceuticals Plans Phase 3 Enozertinib Trial in Lung Cancer for First Half of 2027
ORIC Data Suggest Rinzimetostat May Enhance Prostate Cancer Sensitivity to Androgen Receptor Inhibition
Reuters  ·  10-23
ORIC Data Suggest Rinzimetostat May Enhance Prostate Cancer Sensitivity to Androgen Receptor Inhibition
Oric® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L Nsclc Patients with Egfr Atypical Mutations at Esmo Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
THOMSON REUTERS  ·  10-23
Oric® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L Nsclc Patients with Egfr Atypical Mutations at Esmo Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
Oric Pharmaceuticals - Enozertinib Shows Competitive Safety Profile with no Significant Off-Target Toxicity
THOMSON REUTERS  ·  10-23
Oric Pharmaceuticals - Enozertinib Shows Competitive Safety Profile with no Significant Off-Target Toxicity
Oric Pharmaceuticals - Enozertinib Well Tolerated with no Grade 4/5 Traes or Treatment Discontinuations
THOMSON REUTERS  ·  10-23
Oric Pharmaceuticals - Enozertinib Well Tolerated with no Grade 4/5 Traes or Treatment Discontinuations
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Embla Medical hf (OtherOSSFF) and Molina Healthcare (MOH)
TIPRANKS  ·  10-22
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Embla Medical hf (OtherOSSFF) and Molina Healthcare (MOH)
Oric Pharmaceuticals CFO Dominic Piscitelli Reports Sale of $189,390.60 in Common Shares
Reuters  ·  10-22
Oric Pharmaceuticals CFO Dominic Piscitelli Reports Sale of $189,390.60 in Common Shares
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
GlobeNewswire  ·  10-19
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Wells Fargo Remains a Buy on Oric Pharmaceuticals (ORIC)
TIPRANKS  ·  10-18
Wells Fargo Remains a Buy on Oric Pharmaceuticals (ORIC)

Introduction

Company Name.
Oric Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Issue price:
--